Influence of the serotonin antagonist, metergoline, on the anxiogenic effects of carbon dioxide, and on heart rate and neuroendocrine measures, in healthy volunteers

Human Psychopharmacology

Volumn 16, Issue 3, 2001, Pages 237-245

  Meiri, Gal ^a   Ben Zion, Itzhak Z ^a   Greenberg, Benjamin D ^a   Murphy, Dennis L ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Anxiety; Carbon dioxide; Metergoline; Noradrenaline; Pharmacology; Serotonin

Indexed keywords

CARBON DIOXIDE; METERGOLINE; NORADRENALIN; PLACEBO; PROLACTIN; SEROTONIN; SEROTONIN ANTAGONIST;

AIR; ANGIOGENESIS; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG TOLERABILITY; GAS MIXING; HEART RATE; HUMAN; HUMAN EXPERIMENT; HYPOTHESIS; NEUROENDOCRINE SYSTEM; NORADRENALIN BLOOD LEVEL; NORMAL HUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC SYSTEM; VITAL CAPACITY; VOLUNTEER;

EID: 0035010448     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.259     Document Type: Article

References (62)

1. 5-HT and human anxiety. Evidence from studies using acute tryptophan depletion
2. 2C receptors, respectively
3. 2 challenge in panic disorder: Optimization by receiver operating characteristic (ROC) analysis
4. Daily administration of m-chlorophenyl-piperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects
5. Attenuated response to m-CPP and to pentagastrin after repeated m-CPP in panic disorder
6. Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action
7. 2-induced anxiety in healthy volunteers with the serotonin antagonist metergoline
8. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses
9. 4 receptor cloned from human atrium
10. Replication of action of cholecystokinin tetrapeptide in panic disorder: Clinical and behavioral findings
11. alpha-2-adrenergic receptor sensitivity in panic disorder. II. Cortisol response to clonidine stimulation in panic disorder
12. Endocrine and physiological changes during 'spontaneous' panic attacks
13. Serotonin in the regulation of brain microcirculation
14. Plasma cortisol concentrations preceding lactate-induced panic
15. Simultaneous liquid-chromatographic determination of 3, 4-dihydroxyphenylglycol, catecholamines, and 3, 4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase
16. Hypercapnia and hypoxia: Chemoreceptor-mediated control of locus coeruleus neurons and splanchnic, sympathetic nerves
17. Does metergoline selectively attenuate 5-HT mediated prolactin release?
18. Endocrine profile and therapeutic employment of a new prolactin-lowering drug, metergoline
19. 2 on monoamine metabolism in rat brain
20. Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers
21. Response to hyperventilation in a group of patients with panic disorder
22. Ventilatory physiology of patients with panic disorder
23. High-dose carbon dioxide challenge test in anxiety disorder patients
24. Effect of metergoline on human anxiety
25. Role of 5-HT in stress, anxiety, and depression
26. Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients
27. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research
28. 2 inhalation in the treatment of panic attacks
29. 2 vulnerability in panic disorder
30. [3H] metergoline: A new ligand of serotonin receptors in the rat brain
31. 5-Hydroxytryptamine pathways in anxiety and its treatment
32. Behavioral response to pharmacological challenges: Potentials and pitfalls
33. 1 recognition sites
34. Involvement of 5-HT1, 5-HT2, and 5-HT3 receptors in the mediation of the prolactin response to serotonin and 5-hydroxytryptophan
35. 1C receptors and their therapeutic relevance
36. Ventilatory effects of tryptophan depletion in panic disorder: A preliminary report
37. Effects of tryptophan depletion on anxiety and on panic provoked by carbon dioxide challenge
38. False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis
39. Carbon dioxide as a reciprocal inhibitor in the treatment of neurosis
40. 2C receptors
41. 2-induced anxiety in patients with panic disorder and normal volunteers
42. d-Fenfluramine in panic disorder: A dual role for 5-hydroxytryptamine
43. Further studies of the putative serotonin agonist m-CPP: Evidence for a serotonin receptor-mediated mechanism of action in humans
44. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers
45. Brain serotonin neurotransmission: An overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent actions of serotonergic drugs
46. Pharmacologic effects of toloxatone on reactivity to the 35% carbon dioxide challenge: A single-blind, random, placebo-controlled study
47. 2 challenges
48. 2 in healthy first-degree relatives of patients with panic disorder
49. Modification of 35% carbon dioxide hypersensitivity across 1 week of treatment with clomipramine and fluvoxamine: A double-blind, randomized, placebo-controlled study
50. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder
51. A comparison of the behavioral effects of oral versus intravenous m-CPP administration in OCD patients and the effect of metergoline prior to IV m-CPP
52. Norepinephrine challenges in panic patients
53. Prolactin secretion in man: A useful tool to evaluate the activity of drugs on central 5-hydroxytryptaminergic neurones. Studies with fenfluramine
54. Effects of tryptophan depletion on carbon dioxide provoked panic in panic disorder patients
55. Fenfluramine provocation of anxiety in patients with panic disorder
56. Expression of serotonin receptor mRNAs in blood vessels
57. 2 exposure
58. Discrimination between panic disorder and generalized anxiety disorder by 35% carbon dioxide challenge
59. Developments in the drug treatment of panic disorder: What is the place of the selective serotonin reuptake inhibitors?
60. Panic disorder and the serotonin system
61. Carbon dioxide-induced anxiety. Behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorder and healthy subjects